NCT05959252View on ClinicalTrials.gov

BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

May 1, 2026

Conditions
Extracorporeal Membrane Oxygenation Complication
Interventions
DRUG

Unfractionated heparin

Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL

DRUG

Bivalirudin

Bivalirudin protocol with target aPTT 50-70 seconds

Trial Locations (1)

2050

RECRUITING

Royal Prince Alfred Hospital, Sydney

All Listed Sponsors
lead

Sydney Local Health District

OTHER_GOV